IBOGAINE Act

The IBOGAINE Act aims to accelerate the development and approval of ibogaine and similar compounds for treating addiction, trauma, and serious mental illnesses by modifying federal drug laws. It creates a new voucher system that grants sponsors of breakthrough mental health drugs priority review by the FDA, while also establishing special registration rules to allow physicians to legally administer Schedule I substances to eligible patients under the "right to try" law. The legislation further directs the Department of Veterans Affairs to create a dedicated senior official and workforce plan for emerging therapies, mandates timely rescheduling of ibogaine from Schedule I to Schedule II, and requires federal agencies to share clinical trial data to speed up the approval process.